Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Lymphoma 5Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Arthritis, Rheumatoid 2Off-Label Use 1Lymphoma, Mantle-Cell 1Leukemia, B-Cell 1Infections 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Etanercept 6Adalimumab 6Infliximab 5tocilizumab 3golimumab 3Tumor Necrosis Factor Inhibitors 3tofacitinib 2Rituximab 2Certolizumab Pegol 2Surveys and Questionnaires 1Standard of Care 1Practice Guidelines as Topic 1Phlebotomy 1Observation 1Methods 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Dietary Fiber 1CT-P13 1Antirheumatic Agents 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Arthritis, Rheumatoid × Rituximab × Clear all
NCT01613027 2016-10-24

An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

Hoffmann-La Roche

Completed
135 enrolled 21 charts

Arthritis, Rheumatoid

NCT01641952 2016-08-17

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent

Hoffmann-La Roche

Completed
505 enrolled 15 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡